{"transactions":[{"id":739880,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:37:11.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":15.48,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001840663-26-000002","document":"form4-06122026_080608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000184066326000002/form4-06122026_080608.xml","form_type":"4"}},{"id":1070278,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-11T20:14:24.000Z","date":"2025-08-07","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":4.32,"expiration_date":"2035-08-06","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-021423","document":"form4-08112025_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925021423/form4-08112025_080820.xml","form_type":"4"}},{"id":1392100,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T23:19:49.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":25306,"price":19.9,"value":503589.4,"ownership":{"direct":false,"nature":"Andreessen Horowitz LSV Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.78 to $19.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Andreessen Horowitz LSV Fund III, L.P. (\"AH LSV Fund III\"), for itself and as nominee for Andreessen Horowitz LSV Fund III-B, L.P. (\"AH LSV Fund III-B\") and AH 2022 Annual Fund, L.P. (\"AH 2022 Annual\" and together with AH LSV Fund III and AH LSV Fund III-B, the \"AH LSV Fund III Entities\"). AH Equity Partners LSV III, L.L.C. (\"AH EP LSV III\"), the general partner of AH LSV Fund III and AH LSV Fund III-B, may be deemed to have sole voting and dispositive power over the shares held by AH LSV Fund III and AH LSV Fund III-B. AH Equity Partners 2022 Annual Fund, L.L.C. (\"AH EP 2022 Annual\"), the general partner of AH 2022 Annual, may be deemed to have sole voting and dispositive power over the shares held by AH 2022 Annual."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The managing members of each of: (i) AH EP Bio I; (ii) AH EP Bio III; (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."}],"balance_after":1119195,"source":{"system":"sec-edgar","filing":"0001415889-24-024688","document":"form4-10032024_111046.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024688/form4-10032024_111046.xml","form_type":"4"}},{"id":1392099,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T23:19:49.000Z","date":"2024-10-02","kind":"purchase","planned":false,"acquired":true,"shares":67096,"price":19.73,"value":1323804.08,"ownership":{"direct":false,"nature":"Andreessen Horowitz LSV Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.50 to $19.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Andreessen Horowitz LSV Fund III, L.P. (\"AH LSV Fund III\"), for itself and as nominee for Andreessen Horowitz LSV Fund III-B, L.P. (\"AH LSV Fund III-B\") and AH 2022 Annual Fund, L.P. (\"AH 2022 Annual\" and together with AH LSV Fund III and AH LSV Fund III-B, the \"AH LSV Fund III Entities\"). AH Equity Partners LSV III, L.L.C. (\"AH EP LSV III\"), the general partner of AH LSV Fund III and AH LSV Fund III-B, may be deemed to have sole voting and dispositive power over the shares held by AH LSV Fund III and AH LSV Fund III-B. AH Equity Partners 2022 Annual Fund, L.L.C. (\"AH EP 2022 Annual\"), the general partner of AH 2022 Annual, may be deemed to have sole voting and dispositive power over the shares held by AH 2022 Annual."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The managing members of each of: (i) AH EP Bio I; (ii) AH EP Bio III; (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."}],"balance_after":1093889,"source":{"system":"sec-edgar","filing":"0001415889-24-024688","document":"form4-10032024_111046.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024688/form4-10032024_111046.xml","form_type":"4"}},{"id":1392098,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T23:19:49.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":126793,"price":19.73,"value":2501625.89,"ownership":{"direct":false,"nature":"Andreessen Horowitz LSV Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.49 to $20.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Andreessen Horowitz LSV Fund III, L.P. (\"AH LSV Fund III\"), for itself and as nominee for Andreessen Horowitz LSV Fund III-B, L.P. (\"AH LSV Fund III-B\") and AH 2022 Annual Fund, L.P. (\"AH 2022 Annual\" and together with AH LSV Fund III and AH LSV Fund III-B, the \"AH LSV Fund III Entities\"). AH Equity Partners LSV III, L.L.C. (\"AH EP LSV III\"), the general partner of AH LSV Fund III and AH LSV Fund III-B, may be deemed to have sole voting and dispositive power over the shares held by AH LSV Fund III and AH LSV Fund III-B. AH Equity Partners 2022 Annual Fund, L.L.C. (\"AH EP 2022 Annual\"), the general partner of AH 2022 Annual, may be deemed to have sole voting and dispositive power over the shares held by AH 2022 Annual."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The managing members of each of: (i) AH EP Bio I; (ii) AH EP Bio III; (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."}],"balance_after":1026793,"source":{"system":"sec-edgar","filing":"0001415889-24-024688","document":"form4-10032024_111046.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024688/form4-10032024_111046.xml","form_type":"4"}},{"id":1398493,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":2924318,"ownership":{"direct":false,"nature":"AH Bio Fund IV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported in this row are held by AH Bio Fund IV, L.P., for itself and as nominee for:  (i) AH Bio Fund IV-B, L.P.; (ii) AH 2022 Annual Fund, L.P.; (iii) AH 2022 Annual Fund-B, L.P.; (iv) AH 2022 Annual Fund-QC, L.P.; and (v) CLF Partners III, LP (collectively, the \"AH Bio Fund IV Entities\").  AH Equity Partners Bio IV, L.L.C. (\"AH EP Bio IV\") is the general partner of the AH Bio Fund IV Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":655294},"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398492,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":846152,"ownership":{"direct":false,"nature":"AH Bio Fund III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities reported in this row are held by AH Bio Fund III, L.P., for itself and as nominee for AH Bio Fund III-B, L.P. and AH Bio Fund III-Q, L.P. (collectively, the \"AH Bio Fund III Entities\").  AH Equity Partners Bio III, L.L.C. (\"AH EP Bio III\") is the general partner of the AH Bio Fund III Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":189609},"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398491,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":1843502,"ownership":{"direct":false,"nature":"AH Bio Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are held by AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P. (collectively, the \"AH Bio Fund I Entities\").  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\") is the general partner of the AH Bio Fund I Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":413100},"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398490,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":3819863,"ownership":{"direct":false,"nature":"AH Bio Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are held by AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P. (collectively, the \"AH Bio Fund I Entities\").  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\") is the general partner of the AH Bio Fund I Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":855972},"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398489,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":900000,"price":18,"value":16200000.0,"ownership":{"direct":false,"nature":"Andreessen Horowitz LSV Fund III, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities reported in this row are held by Andreessen Horowitz LSV Fund III, L.P. (\"AH LSV Fund III\"), for itself and as nominee for Andreessen Horowitz LSV Fund III-B, L.P. (\"AH LSV Fund III-B\") and AH 2022 Annual Fund, L.P. (\"AH 2022 Annual\" and, collectively with AH LSV Fund III and AH LSV Fund III-B, the \"AH LSV Fund III Entities\"). AH Equity Partners LSV III, L.L.C. (\"AH EP LSV III\") is the general partner of AH LSV Fund III and AH LSV Fund III-B and may be deemed to exercise voting and investment discretion with respect to securities directly held by them.  AH Equity Partners 2022 Annual Fund, L.L.C. (\"AH EP 2022 Annual\") is the general partner of AH 2022 Annual and may be deemed to exercise voting and investment discretion with respect to securities directly held by it.  The AH Bio Fund I Entities, the AH Bio Fund III Entities, the AH Bio Fund IV Entities and the AH LSV Fund III Entities are collectively referred to herein as the \"AH Fund Entities.\""}],"balance_after":900000,"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398488,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":655294,"ownership":{"direct":false,"nature":"AH Bio Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported in this row are held by AH Bio Fund IV, L.P., for itself and as nominee for:  (i) AH Bio Fund IV-B, L.P.; (ii) AH 2022 Annual Fund, L.P.; (iii) AH 2022 Annual Fund-B, L.P.; (iv) AH 2022 Annual Fund-QC, L.P.; and (v) CLF Partners III, LP (collectively, the \"AH Bio Fund IV Entities\").  AH Equity Partners Bio IV, L.L.C. (\"AH EP Bio IV\") is the general partner of the AH Bio Fund IV Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."}],"balance_after":655294,"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398487,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":189609,"ownership":{"direct":false,"nature":"AH Bio Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities reported in this row are held by AH Bio Fund III, L.P., for itself and as nominee for AH Bio Fund III-B, L.P. and AH Bio Fund III-Q, L.P. (collectively, the \"AH Bio Fund III Entities\").  AH Equity Partners Bio III, L.L.C. (\"AH EP Bio III\") is the general partner of the AH Bio Fund III Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."}],"balance_after":189609,"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398486,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":413100,"ownership":{"direct":false,"nature":"AH Bio Fund I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are held by AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P. (collectively, the \"AH Bio Fund I Entities\").  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\") is the general partner of the AH Bio Fund I Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":1269072,"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1398485,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:28:00.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":855972,"ownership":{"direct":false,"nature":"AH Bio Fund I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported in this row are held by AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P. (collectively, the \"AH Bio Fund I Entities\").  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\") is the general partner of the AH Bio Fund I Entities and may be deemed to exercise voting and investment discretion with respect to securities directly held by them."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing members of each of:  (i) AH EP Bio I; (ii) AH EP Bio III;  (iii) AH EP Bio IV; (iv) AH EP LSV III; and (v) AH EP 2022 Annual (collectively, the \"AH GP Entities\") are Marc Andreessen and Ben Horowitz, and each of them may be deemed to share voting and investment discretion with respect to securities directly held by the AH Fund Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person serves as one of the members of the AH GP Entities, but he disclaims the existence of a \"group\" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")), and disclaims beneficial ownership of the securities directly held by the AH Fund Entities, and this report shall not be deemed an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":855972,"source":{"system":"sec-edgar","filing":"0001415889-24-024047","document":"form4-09272024_080956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024047/form4-09272024_080956.xml","form_type":"4"}},{"id":1477409,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T21:35:30.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-24-000049","document":"wk-form4_1718660123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000049/wk-form4_1718660123.xml","form_type":"4"}},{"id":1852485,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:52:19.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-23-000060","document":"wf-form4_168695952896084.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000060/wf-form4_168695952896084.xml","form_type":"4"}},{"id":2230108,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T00:03:04.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":86467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":86467,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":86467},"source":{"system":"sec-edgar","filing":"0001808805-22-000068","document":"wf-form4_165542416822735.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000068/wf-form4_165542416822735.xml","form_type":"4"}}]}